Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 3/20 | 0.58 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.58 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.58 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.58 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.58 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.58 |
| ▸ | TFPI | P10646 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | CTSD | P07339 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | GLP1R | P43220 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pexiganan SCHEMBL15247673 | 1.00 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Pexiganan SCHEMBL17513878 | 1.00 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29405313 | 1.00 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Pexiganan SCHEMBL487091 | 0.99 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Acetic Acid SCHEMBL29396321 | 0.99 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29458126 | 0.91 | GLP1R (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29716608 | 0.91 | GLP1R (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29420210 | 0.90 | TFPI (0.53) | TFPIF2 | |
| SCHEMBL30567725 | 0.89 | BACE1 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30950136 | 0.87 | GLP1R (0.65) | TFPIGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 957 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570688-B2 | Activated cysteine-directed polypeptide ligation technique | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2026-03-10 | — | — | US | claimed |
| US-12377186-B2 | Antimicrobial biopolymer compositions, methods of synthesis, and applications of use | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-08-05 | — | — | US | claimed |
| US-20250195660-A1 | INACTIVATING BACTERIA WITH ELECTRIC PULSES AND ANTIBIOTICS | PURDUE RESEARCH FOUNDATION (US) | 2025-06-19 | — | — | US | claimed |
| CN-119745792-A | Eye drop containing pexiganan modified hyaluronic acid, preparation method and application | 济南万泉生物技术有限公司 | 2025-04-04 | — | — | CN | claimed |
| US-12251439-B2 | Inactivating bacteria with electric pulses and antibiotics | PURDUE RESEARCH FOUNDATION (US) | 2025-03-18 | — | — | US | claimed |
| US-20240391965-A1 | STAPLED ANTIMICROBIAL PEPTIDES (STAMPS) AND USES THEREOF | LYTICA THERAPEUTICS, INC. (US) | 2024-11-28 | — | — | US | claimed |
| WO-2024199558-A1 | METHOD OF PRODUCTION OF FIBERS AND A DEVICE FOR CARRYING OUT THE METHOD | CONTIPRO A.S. (CZ) | 2024-10-03 | — | — | WO | claimed |
| EP-4413184-A1 | METHOD OF PREPARATION OF FIBRES AND DEVICE FOR CARRYING OUT THIS METHOD | Contipro a.s. (CZ) | 2024-08-14 | — | — | EP | claimed |
| US-20240247035-A1 | STAPLED ANTIMICROBIAL PEPTIDES (STAMPS) AND USES THEREOF | LYTICA THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | US | claimed |
| US-20240174723-A1 | STAPLED ANTIMICROBIAL PEPTIDES (STAMPS) AND USES THEREOF | LYTICA THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | US | claimed |
| US-8003348-B2 | Method for the mass expression of an antimicrobial peptide by co-expression of a basic antimicrobial peptide and an acidic peptide using a translational coupling system | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-08-23 | — | — | US | claimed |
| WO-2011069280-A1 | ANTIMICROBIAL PEXIGANAN ANALOGUE AND PREPARATION PROCESS THEREOF | WU XIAOYAN (CN) | 2011-06-16 | — | — | WO | claimed |
| WO-2011049960-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SINONASAL DISORDERS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | claimed |
| WO-2011050206-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SINONASAL DISORDERS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | claimed |
| WO-2011049958-A2 | MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | claimed |
| US-20100184949-A1 | Method for the mass expression of an antimicrobial peptide by using a translational coupling system | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-07-22 | — | — | US | claimed |
| WO-2009070564-A2 | COMPOSITIONS AND METHODS FOR PREVENTION OF INFECTION IN TRANSCUTANEOUS OSSEOINTEGRATED IMPLANTS | MACROCHEM CORPORATION (US) | 2009-06-04 | — | — | WO | claimed |
| WO-2008058016-A2 | ETHOID-CONTAINING COMPOUNDS, METHODS FOR PREPARING ETHOID-CONTAINING COMPOUNDS, AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-05-15 | — | — | WO | claimed |
| CN-1920020-A | Gene engineering producing method of antibacterial peptide Pexiganan | TIANJIN TASLY PHARMACEUTICAL (CN) | 2007-02-28 | — | — | CN | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570688-B2 | Activated cysteine-directed polypeptide ligation technique | PTMS, LNPEP, ANPEP | PSEN1 4800/4885PSEN2 4645/4885APH1B 1927/4885 |
| US-20240391965-A1 | STAPLED ANTIMICROBIAL PEPTIDES (STAMPS) AND USES THEREOF | NGLY1, SAMSN1, SDAD1 | PSEN1 1829/4885PSEN2 2848/4885APH1B 863/4885 |
| US-20240247035-A1 | STAPLED ANTIMICROBIAL PEPTIDES (STAMPS) AND USES THEREOF | NGLY1, SPPL2B, SPPL2A | PSEN1 1222/4885PSEN2 1927/4885APH1B 219/4885 |
| US-20240174723-A1 | STAPLED ANTIMICROBIAL PEPTIDES (STAMPS) AND USES THEREOF | NGLY1, MDN1, SPPL2B | PSEN1 2373/4885PSEN2 1472/4885APH1B 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.